Ouro launches with $115M and a clinical-stage T-cell engager
8 hours ago · Ouro Medicines launched Friday with the goal of harnessing T cells to reset the immune systems of patients with chronic immune diseases. Ouro launches with $115M and a clinical-stage T-cell engager
Ouro Medicines Launches to Define the Future of Treatment for …
9 hours ago · Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...
GSK-backed Ouro Launches With $115M to ‘Reset’ the Immune …
9 hours ago · Ouro hopes to leverage T cell engagers to specifically address B cell disorders. T cell engagers are bispecific antibodies designed to target and deplete certain disease-causing populations of cells. Ouro plans to leverage this approach to “reset” the immune system—that is, eliminate pathogenic B cells to bring the immune system back to a ...
Ouro Medicines Launches to Define the Future of Treatment for …
9 hours ago · News provided by Ouro Medicines Jan 10, 2025, 06:00 ET. Share this article. Share to X. Share this article. Share to X. Ouro will ...
Ouro Medicines Launches to Define the Future of Treatment for …
Ouro Medicines is a biotechnology company dedicated to developing immune reset therapeutics for people living with chronic immune-mediated diseases. Ouro's approach is focused on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that create durable remissions without ongoing immunosuppression.
Ouro Medicines Launches to Define the Future of Treatment
8 hours ago · SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced ...
Ouro, backed by GSK, joins hunt to bring bispecifics to ... - Yahoo
20 hours ago · Ouro is now part of that group. Like Candid, it starts with a drug licensed from a China-based biotech company and originally tested in cancer.Dubbed OM336, the drug targets BCMA, a protein ...
TPG : Ouro Medicines Launches to Define the Future of Treatment …
5 hours ago · Ouro's approach is focused on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that create durable remissions without ongoing immunosuppression. Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also …
With $120M, GSK-allied Ouro Medicines throws its hat into …
9 hours ago · With $120M, GSK-allied Ouro Medicines throws its hat into burgeoning TCE ring. Kyle LaHucik ... BREAKING NEWS ALERTS 2-3 times a week. ENDPOINTS FDA+ Wed at 2 PM ET.
ouro medicines News & Press Releases | PR Newswire
News from ouro medicines A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health ...
- Some results have been removed